Comparative Pharmacology
Head-to-head clinical analysis: LEVOLET versus LIOTHYRONINE SODIUM.
Peer-Reviewed Evidence
Head-to-head clinical analysis: LEVOLET versus LIOTHYRONINE SODIUM.
LEVOLET vs LIOTHYRONINE SODIUM
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Levolet (levothyroxine) is a synthetic thyroid hormone that replaces endogenous thyroxine (T4). It is converted to triiodothyronine (T3) in peripheral tissues, which binds to thyroid hormone receptors to regulate gene expression, increasing metabolic rate and protein synthesis.
Liothyronine is a synthetic form of triiodothyronine (T3), the active thyroid hormone. It binds to thyroid hormone receptors in the nucleus, modulating gene transcription and increasing basal metabolic rate, oxygen consumption, and thermogenesis. It enhances carbohydrate and lipid metabolism, and promotes normal growth and development.
Levofloxacin 500 mg orally or intravenously once daily for 5-14 days depending on indication.
25-75 mcg orally once daily; initial dose 25 mcg daily, titrate by 12.5-25 mcg increments every 1-2 weeks based on response.
None Documented
None Documented
Terminal elimination half-life: 6-8 hours; shorter in patients with hepatic impairment.
Approximately 1-2 days in euthyroid patients; shorter in hyperthyroidism, prolonged in hypothyroidism. Clinical context: requires monitoring of thyroid function tests for dose adjustment.
Renal: 70-80% unchanged, biliary/fecal: 20-30% as metabolites.
Primarily renal (approximately 50% as unchanged drug and metabolites); minor biliary/fecal elimination.
Category C
Category A/B
Thyroid Hormone
Thyroid Hormone